Navigation Links
DuoCort: New chronotherapy for adrenal insufficiency
Date:6/29/2009

drenal hyperplasia.

About chronotherapy
Coordinating biological rhythms (chronobiology) with medical treatment is called chronotherapy. It takes into account the body's biological rhythms in determining the timing--and sometimes the amount--of medication to optimize a drug's desired effects and minimize its undesired ones.
Chronotherapy for the most part is not about new drug substances but about using medicines in new ways, better attuned to the bodys needs. Designing a drug so its release into the bloodstream has a particular release pattern or using pumps that deliver medicine at specified intervals are some of the innovations that may reap important benefits.

About DuoCort
DuoCort is a drug development company focused on improving glucocorticoid therapy in several areas of medical need. The company has its origins among researchers at the Sahlgrenska University Hospital in Gothenburg and at Uppsala University in Sweden. DuoCort is developing an improved glucocorticoid replacement therapy for patients with adrenal insufficiency, a rare disease for which DuoCort has orphan drug designations in Europe and the USA. The new product, a once daily dual-release hydrocortisone oral tablet that comes in both 5 mg and 20 mg sizes, is being developed by DuoCort Pharma AB, a wholly-owned subsidiary. For more information on DuoCort please visit www.duocort.com

Contact information
Medical spokesperson: Gudmundur Johannsson Tel +46 705 280 872
Corporate spokesperson: Maria Forss Tel +46 709 670 007


'/>"/>
b3c newswire

Page: 1 2 3

Related biology news :

1. Doctors may be giving the wrong dosage of adrenaline in an emergency because of labelling
2. Vitamin D insufficiency linked to bacterial vaginosis in pregnant women
3. Researchers identify a molecule that increases the risk of cardiac insufficiency
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... biologists, led by Clemson University associate professor Andrew S. ... will pave the way for novel anti-fouling paint for ... and industrial applications. , The team,s findings, published in ... larval stage of barnacles that attaches to a wide ... material that acts as an underwater heavy-duty adhesive. , ...
(Date:7/30/2014)... Portland Press Limited today announced an across-the-board increase ... , The 2013 InCites Journal Citation Reports (Thomson ... Biochemical Journal , Essays in Biochemistry ... Bioscience Reports all received increases in their ... Biochemical Society and published by Portland Press Limited. ...
(Date:7/30/2014)... A professor from Wayne State University,s College of ... National Science Foundation for the project, "Nanoparticle-directed synthesis ... National Science Foundation, nanotechnology is the creation and ... novel properties and functions. A major bottleneck in ... methods that connect different functional materials into one ...
Breaking Biology News(10 mins):Study: Marine pest provides advances in maritime anti-fouling and biomedicine 2Across-the-board Impact Factor increases for Portland Press Limited 2NSF grant to Wayne State supports new concept for manufacturing nanoscale devices 2
... have created the first three-dimensional living tissue model, complete ... therapeutics to combat brain tumors. The 3-D model gives ... tissue cultures. The researchers created a glioma, or ... surrounds it. In a series of experiments, the team ...
... have succeeded in changing the genetic material of cancer ... in nanosurgery opens the door to new medical applications, ... A light scalpel to treat cancerous cells, The ... team uses a femtosecond laser (a laser with ultra-short ...
... Resolving the world,s major challenges whether climate change, ... scarcity requires a sweeping shift in our approach ... leading scientists told European policy makers today during ... and Societal Challenges for our Unstable Earth" (RESCUE). ...
Cached Biology News:Researchers make living model of brain tumor 2Europe needs a 'RESCUE' revolution 2Europe needs a 'RESCUE' revolution 3
(Date:7/30/2014)... , July 30, 2014  Orexigen Therapeutics, Inc. (Nasdaq: ... the Day 180 List of Outstanding Issues (LOI) from ... Human Use (CHMP) for the NB32 Marketing Authorization Application ... is an investigational drug candidate being evaluated for weight ... Day 120 time point were adequately addressed by the ...
(Date:7/30/2014)...  AtheroNova Inc. (OTCBB: AHRO), a biotech company ... to safely regress atherosclerotic plaque and improve lipid ... CardioNova, has accomplished first dosing of subjects for ... compound, AHRO-001.  This Phase 1b trial will be ... trial completed in February 2014, in which patients ...
(Date:7/30/2014)... July 30, 2014 Vala Sciences ... U.S. Environmental Protection Agency (EPA). This new contract ... toxicity models, including tests designed to assess the ... the formation of connections between neurons (synapses), which ... and synapse formation by environmental pollutants likely contributes ...
(Date:7/29/2014)... July 30, 2014 SoundConnect ... collaboration company, is proud to announce the strategic ... positions in their Boston, Charleston and Atlanta offices. ... the increased demand for hosted solutions, collaboration and ... and reduce cost. , SoundConnect was founded in ...
Breaking Biology Technology:Orexigen Receives CHMP Day 180 List of Outstanding Issues 2Orexigen Receives CHMP Day 180 List of Outstanding Issues 3AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 2AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 3AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 4U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 2U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 3SoundConnect Organization and Culture is Evolving 2
... July 14 Bio-Optronics, Inc., a leader in healthcare workflow ... software solution that can simultaneously handle the most intricate scheduling ... staff schedules. , , Physician ... , Bio-Optronics President & CEO, ...
... , HALIFAX, NS, July 14 /PRNewswire/ - ImmunoVaccine ... entered into an agreement to exclusively license seven ... company. These proprietary antigens specifically target breast, ovarian ... antigens with its DepoVax(TM) delivery platform to develop ...
... , , TAMPA, Fla., July ... on the research and development of cancer immunotherapies, announces that the ... its dendritic cell therapy. , , ... I/II clinical trial testing the safety and efficacy of its immunotherapy ...
Cached Biology Technology:NEW Momentum(TM) Physician and Staff Scheduling Software for Imaging Centers, OB/GYN, and Other Specialty Practices Improves Productivity and Equity in Scheduling 2ImmunoVaccine Technologies Licenses Immunotope's Breast, Ovarian and Prostate Cancer Antigens 2Significant Milestone Marks the Beginning of FDA-Authorized Breast Cancer Trial 2Significant Milestone Marks the Beginning of FDA-Authorized Breast Cancer Trial 3